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Abstract
Background: The clinical efficacy of camptothecin (CPT), a drug specifically targeting
topoisomerase I (TopoI), is under evaluation for the treatment of malignant gliomas. Due to the
high unresponsiveness of these tumours to chemotherapy, it would be very important to study the
signalling network that drives camptothecin outcome in this type of cancer cells. To address this
issue, we had previously compared the expression profile of human U87-MG glioblastoma cells
with that of a CPT-resistant counterpart, giving evidence that the development of a robust
inflammatory response was the main transcriptional effect associated with CPT resistance.
Here we report time-related changes and cell line specific patterns of gene expression after CPT
treatment by using two p53 wild-type glioblastoma cell lines, U87-MG and DBTRG-05, with
different sensitivities to TopoI inhibition.
Results: First, we demonstrated that CPT treatment brings the two cell lines to completely
different outcomes: accelerated senescence in U87-MG and apoptosis in DBTRG-05 cells. Then, to
understand the different susceptibility to CPT, we used oligo-microarray to identify the genes
whose expression was regulated during a time-course treatment, ranging from 2 h to 72 h. The
statistical analysis of microarray data by MAANOVA (MicroArray ANalysis Of VAriance) showed
much less modulated genes in apoptotic DBTRG-05 cells (155) with respect to the senescent U87-
MG cells (3168), where the number of down-regulated genes largely exceeded that of the up-
regulated ones (80% vs. 20%). Despite this great difference, the two data-sets showed a large
overlapping (60% circa) mainly due to the expression of early stress responsive genes. The use of
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Molecular Cancer 2008, 7:66 http://www.molecular-cancer.com/content/7/1/66High-Throughput GoMINER and EASE tools, for functional analysis of significantly enriched GO
terms, highlighted common cellular processes and showed that U87-MG and DBTRG-05 cells
shared many GO terms, which are related to the down-regulation of cell cycle and mitosis and to
the up-regulation of cell growth inhibition and DNA damage.
Furthermore, the down-regulation of MYC and DP1 genes, which act as key transcription factors
in cell growth control, together with the inhibition of BUB1, BUB3 and MAD2 mRNAs, which are
known to be involved in the spindle checkpoint pathway, were specifically associated with the
execution of senescence in U87-MG cells and addressed as critical factors that could drive the
choice between different CPT-inducible effectors programs. In U87-MG cells we also found
inflammation response and IL1-beta induction, as late transcriptional effects of Topo I treatment
but these changes were only partially involved in the senescence development, as shown by IL1-
beta gene silencing.
Conclusion: By comparing the transcription profile of two glioblastoma cell lines treated with
camptothecin, we were able to identify the common cellular pathways activated upon Topo I
inhibition. Moreover, our results helped in identifying some key genes whose expression seemed
to be associated with the execution of senescence or apoptosis in U87-MG and DBTRG-05 cells,
respectively.
Background
Camptothecin, a naturally occurring cytotoxic alkaloid,
and its water-soluble derivatives belong to a family of
antineoplastic agents specifically targeting topoisomerase
I. They exert their main S-phase cytotoxic activity through
the accumulation of DNA double-strand breaks, originat-
ing from the collision between the replication fork and
the ternary complex TopoI-CPT-DNA [1,2]. In general,
CPT treatment arrests cells in G2 phase and can trigger
rapid apoptosis in some cell types [3]. However, in the
presence of low CPT doses and limited DNA damage
extension, the induction of a senescence-like-phenotype
(SLP) was observed [4-6]
Most of the molecular events elicited by CPT deal with
stress response and cell survival signaling pathways acti-
vated by DNA damage [7,8]. Beside the ATM/Chk2 DNA
damage checkpoint pathway, the ATR-Chk1 response has
recently been described to play a predominant role in the
response to TopoI inhibition [9]. Furthermore, in many
cellular systems, CPT was able to activate NF-kB, a key
transcriptional factor that regulates the survival response
induced by many chemotherapeutics [10,11]. All these
pathways clearly converge on the transcriptional machin-
ery, thus affecting the transcriptome in a relevant manner.
For this reason, a global analysis of gene expression mod-
ulation by microarray could produce new insights into the
complexity of TopoI poisons stress responses [12].
The transcriptional profile of CPT effects has been deter-
mined in HCT116 synchronized human colon cancer
cells, in a time-series study, by treating cells with relatively
low (20 nM) and high (1000 nM) drug concentrations
[13]. A microarray analysis was also reported for HeLa
cells and ML-2 myeloid leukemia cells, in a single-time
treatment experiment with a CPT concentration able to
induce apoptosis [3,14]. Recently, the changes in gene
expression, following the short-term exposure of HL60
cells, to SN-38, the active metabolite of camptothecin,
were compared with those derived from the peripheral
blasts of patients with acute and chronic myeloid leuke-
mia, that had undergone a therapy with a single dose of
Irinotecan (CPT-11), a water soluble derivative of camp-
tothecin [15]. This study showed a number of genes
whose expression was commonly affected by CPT-11 both
in vitro and in vivo. In addition, Reinhold et al. investigated
the mechanism of CPT-11 resistance in DU145 human
prostate cancer cells, by using microarray technology and
analysis [16].
All these studies were useful to generate new hypothesis
on the mechanisms of Topo1 inhibition that were unpre-
dictable on the basis of the known properties of the drug.
As the use of camptothecins is under evaluation for the
treatment of malignant gliomas [17,18], we previously
analysed the transcriptional profile of CPT resistant U87-
MG glioma cells, obtained from repeated exposures of the
parental cell line to a high CPT concentration [19]. Our
results had demonstrated that many of the most up-regu-
lated genes trigger cellular mechanisms, like inflamma-
tory response and angiogenesis, that can negatively
impact upon chemotherapy efficacy.
To clarify the effects of TopoI inhibition in glioblastoma
cells, in the present study we first checked the sensitivity
of two human glioblastoma cell lines, U87-MG and
DBTRG-05, to CPT and, then, we characterized the CPT-Page 2 of 16
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course treatment ranging from 2 to 72 hours, by using
high density oligonucleotide (60-mer) array technology.
Although the two cell lines are both representative of high
grade glioblastoma and are considered p53 wild-type,
DBTRG-05 cells underwent mainly apoptosis while U87-
MG cells developed a senescence-like phenotype.
The expression profiling showed the common biological
processes that are modulated by TopoI in both cell lines
and identified specific gene networks linked to the devel-
opment of senescence in U87-MG cells. Apoptosis and
senescence are considered two alternative mechanisms of
the chemotherapy-induced tumor repression. Many ques-
tions, however, still, remain open about the effective role
that accelerated senescence has in a clinical setting,
mainly due to its potential detrimental effects [20-22].
Therefore, the transcriptional analysis of the mechanisms
underlying the execution of two distinct camptothecin
effectors programs could help in better understanding the
final outcome of TopoI poisoning.
Results
CPT treatment promotes a senescence-like phenotype in 
U87-MG cells but induces apoptosis in DBTRG-05 cells
The effect of CPT on glioblastoma cells was first assessed
by the crystal violet growth inhibition assay. The dose-
response curves from a 72-hour treatment with different
concentrations of CPT, were used to calculate the GI50
values (50% Growth Inhibition). As shown in Figure 1A,
DBTRG-05 cells are more sensitive to TopoI inhibition,
being the GI50 value five times lower in this cell line
(0.018 μM) than in U87-MG cells (0.09 μM).
The ability of CPT to induce apoptosis was then analyzed
in both cell lines, by using the Annexin-V method (Figure
1B). Even if the positive control (actinomycin D plus TNF
alpha) triggered a similar response in the two cell lines,
only DBTRG-05 cells showed a significant induction of
apoptosis, after 24 h-treatment with CPT, even at the
lower assayed dose of 0.05 μM. U87-MG cells remained
substantially refractory to apoptosis, at all the assayed
concentrations except for a slight effect (13.9%) detected
at the dose 5 μM CPT. These data were further confirmed
by using CPT at the concentrations of 0.2 μM and 1 μM,
for DBTRG-05 and U87-MG cells, respectively (Figure 2).
These doses were extrapolated from the linear regression
curves, as showed in Figure 1A, to give a similar growth
inhibitory effect, on both cell lines, with a maximum
effect (100% growth inhibition) after 72-hours treatment.
Camptothecin was able to induce a significant increase of
apoptosis in DBTRG-05 cells, after 24 and 72 hours treat-
ments, while no up-regulation of annexin-V positive cells
was observed in the U87-MG population (Figure 2A and
2B).
The cell cycle distribution of the two cell lines, in response
to CPT treatment, was then assessed by using flow cytom-
etry after pulse-BrdU incorporation. DNA TopoI inhibi-
tion caused almost similar effects on the two cell lines,
during a time-course treatment ranging from 2 to 72
hours (Figure 3A). Both U87-MG and DBTRG-05 cells
underwent a considerable G2/M arrest (U87 72 h/U87
NT: 27.9%/19.6%; DBTRG 72 h/DBTRG NT:33.8%/
12.6%) with a concomitant increase in the percentage of
non-cycling S-phase cells at all the tested time intervals. A
slight increase in the population of cells with a DNA con-
tent above 4N (6.6%) was observed in U87-MG cells 72
hours after CPT exposure. The apparent recovery of BrdU-
CPT-induced acute citotoxicity and apoptosisFigure 1
CPT-induced acute citotoxicity and apoptosis. A. 
Dose-response analysis of CPT effects on U87-MG and 
DBTRG-05 cells. On Y-axis the percentage of growth, calcu-
lated according to the protocol used by the National Cancer 
Institute, is reported. The GI50 values for both cell lines 
were calculated by linear regression analysis of the log (dose/
effect) curve. B. Annexin-V apoptosis assay was performed 
after a 24-h treatment with 0.5 and 5 μM CPT. DMSO and 
TNF-alpha plus actinomycin D were used as negative and 
positive controls, respectively. Each data point is the average 
of three independent experiments; bars, standard errors.Page 3 of 16
(page number not for citation purposes)
Molecular Cancer 2008, 7:66 http://www.molecular-cancer.com/content/7/1/66positive cells, that we observed after 16 h and 24 h from
the treatments, was associated to the aspecific fluores-
cence caused by CPT, as shown by the shift to the right of
the 16 h- and 24 h-S phase monoparametric curves and by
the microscope analysis of cells under fluorescence (data
not shown). The FACS data, together with the observation
that U87-MG cells became flatter with enlarged nuclei in
response to CPT, suggested that TopoI inhibition could
elicit a senescence-like phenotype in this cell line. We then
investigated the expression of senescence-associated beta-
galactosidase activity (SA-β-gal) and showed that U87-
MG cells stained significantly positive for SA-β-Gal, after a
72-hours treatment with 1 μM CPT (Figure 3B).
Microarray analysis of time course treatment with CPT
To better characterize the molecular mechanisms underly-
ing the response to CPT, we next analyzed the changes in
gene expression, during a time-course treatment ranging
from 2 to 72 hours, with the drug concentrations of 0.2
μM for DBTRG-05 cells and 1 μM for U87-MG cells. For
this purpose, we used high density oligonucleotide (60
mer) microarrays containing more than 17.000 unique
probes (Human1A oligo microarray, G4110A, Agilent
Technologies, Palo Alto, CA).
The statistical analysis of the two time-series data sets was
performed with MAANOVA, a collection of functions for
the statistical analysis of gene expression data from two-
color cDNA microarray experiments that is implemented
as an add-on package for the freely available and widely
used statistical language/software R (see details in materi-
als and methods) [23].
The lists of differentially expressed genes were numerically
completely different. Applying a p-value threshold of 0.01
and 0.05 for U87-MG and DBTRG-05 cells respectively,
the total number of differentially expressed genes was
3168 in the U87- and only 155 in the case of the DBTRG-
05. To facilitate the comparison between the two data-
sets, we restricted the analysis to those genes that reached
a log2 (expression ratio) value above 1.5, at least in one of
the six time-series data points. By doing that, we reduced
the overall number of differentially expressed genes to
713 for U87-MG cells and to 92 for DBTRG cells (see
Additional files 1 and 2 to retrieve the complete lists of
genes returned from MAANOVA analysis and the filtering
process). Based on the time dependent expression profile,
we defined the up- and down-regulated genes within the
two data sets. Interestingly, this analysis, that is summa-
rized in the Venn diagrams reported in Figure 4, demon-
strated that most of the genes, whose expression was
affected by the treatment with CPT, were indeed down-
regulated (almost 80%) in U87-MG cells, while a substan-
tial balance between up- and down-regulation was
observed in the DBTRG-05. Despite this difference, the
two data-sets were largely overlapping, being more than
the 60% of the genes found in DBTRG-05 cells also repre-
sented in the U87-MG population. In Table 1 and Table 2,
we reported the lists of the common up-regulated genes
and the down-regulated ones, respectively. Only four
genes (AREG, MYC, MIG-6 and GEM) showed a different
time-dependent expression profile between the two data-
sets (Figure 5). Indeed, CPT treatment induced the expres-
sion of these genes in DBTRG-05 cells while repressed
them in U87-MG cells. For selected time-points, three of
Apoptotic response of DBTRG-05 and U87-MG cells exposed to CPT working concentrationsFigure 2
Apoptotic response of DBTRG-05 and U87-MG cells exposed to CPT working concentrations. A. Percentages of 
Annexin-V positive DBTRG-05 cells treated for 24 and 72 hours with 0.2 μM CPT. * p < 0.05, Student's t-test. ** p < 0.01, Stu-
dent's t-test. B. Percentages of Annexin-V positive U87-MG cells treated for 24 and 72 hours with 1 μM CPT; bars, standard 
errors. ** p < 0.01, Student's t-test.Page 4 of 16
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firmed through a semi-quantitative RT-PCR analysis,
together with other genes (CDKN1A, TXNIP, GADD45A,
EREG) known to be CPT transcriptional targets (Figure 6).
Taking into account that we used a semi-quantitative
approach, we found overlapping results between two
techniques except for AREG in U87- and EREG in DBTRG-
05 cells whose over-expression was undetectable in micro-
array.
Functional analysis of microarray data through High-
Throughput GoMINER and EASE
To have a general picture of the most affected biological
processes during the time-course treatment, as defined by
Gene Ontology annotation, first we used the High-
Throughput GoMINER analysis tool http://dis
cover.nci.nih.gov/gominer/htgm.jsp[24]. This package
allows the automatic analysis of multiple microarrays and
then integrates the results, across all of them, to find the
GO categories that were significantly over-represented. To
reach this goal the program first estimates the p-value
using Fisher's exact test and then corrects the p-values for
the multiple comparisons by estimating the FDR (False
Discovery Rate).
For each time point, we defined as up-regulated or down-
regulated those genes having a log2(expression ratio)
above 1.5. The results were represented as clustered image
maps (CIM), where the enriched GO categories (FDR <
0.05) are hierarchically clustered (Euclidean distance,
average linkage clustering) against time either for the up-
and the down- regulated genes. (Additional file 3, 4 and
5).
Two main blocks of biological processes were down-regu-
lated in both cell lines treated with CPT. The first was DNA
metabolism (GO:0006260), with all the correlated
molecular mechanisms regulating dNTPs metabolism,
DNA replication and repair, and the second was mitosis
and all the events regarding the regulation of M-phase
(GO:0000087) as well as the formation and maintenance
of the spindle (GO:0007051_spindle_organization
_and_biogenesis). Most of the above biological processes
converged into the main down-regulated process, that was
cell cycle (GO:0007049). In Table 3, we listed the genes
belonging to some of the more representative down-regu-
lated GO categories.
Between the up-regulated GO terms, the response to
DNA-damage stimulus (GO:0006974) and cell cycle
BrdU Flow cytometry assay of U87-MG and DBTRG-05 cells exposed to CPT and SA-β Gal staining in treated U87-MG cellsFigure 3
BrdU Flow cytometry assay of U87-MG and DBTRG-05 cells exposed to CPT and SA-β Gal staining in treated 
U87-MG cells. A. Time dependent changes in DNA content following treatment, from 2 to 72 hours, of U87-MG and 
DBTRG-05 cells with 1 μM and 0.2 μM CPT, respectively. DMSO: solvent control B. SA-β Gal staining of CPT-exposed U87-
MG cells (CPT) versus control (NT). For this purpose, a 72 h treatment with 1 μM CPT was performed. Counts were made on 
three random fields of about 100 cells.
A
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esses that were more significantly affected by CPT in both
cell line.
The two data sets were also analyzed by EASE, a publicly
available and stand-alone application for use on Win-
dows operating systems [25]. We used EASE to identify
the enriched GO-Categories corresponding to "biological
processes" in the list of up and down-regulated genes with
respect to the whole list of genes of the microarray. In
Table 4 we reported only those categories having an EASE
score, corrected for multiple comparisons with the Bon-
ferroni method, below 0.05.
Even if EASE analysis was more restrictive than that of
High-Throughput GoMINER (also due to the choice of the
stringent Bonferroni correction), it gave "cell cycle" and
"DNA metabolism" as common CPT-down-regulated bio-
logical processes in the two glioblastoma cell lines.
No significant enriched GO category was found by EASE
in the list of up-regulated DBTRG genes whereas in U87-
MG cells, besides the "negative regulation of cell prolifer-
ation", the terms "response to stimulus" and "response to
stress" were called as significantly enriched biological
processes. Some of the genes involved in the response to
stress were also implicated in inflammatory response such
as FOS; IL1B; IL8; PRDX5; PROCR and TNFAI.
Role of IL-1beta in senescence development
In apoptotic DBTRG-05 cells we did not find any signifi-
cant modulation of IL1-beta or other genes involved in
inflammation, while IL-1beta over-expression was
observed in U87-MG cells, at the latest time points (48 h
and 72 h) of the time-course.
Taking into account that U87-MG resistance to CPT was
previously suggested to be sustained by IL1-beta up-regu-
lation [19], we decided to investigate the role that the late
expression of IL-1beta could have in the development of
senescence. For this purpose, U87-MG cells were tran-
siently transfected with two different IL-1beta siRNA
(IL1B_4_HPsiRNA and IL1B_6_HPsiRNA, Qiagen) and,
after one day, treated with 1 μM CPT for 72 h. Both siR-
NAs were able to significantly knock down the expression
of IL-1beta, as determined by Real-Time PCR (Figure 7A).
The effect of IL-1beta silencing on the development of
accelerated senescence was evaluated by measuring the
SA-β-gal activity and the cloning efficiency of transfected
cells (Figure 7B and 7C).
Discussion
We adopted oligo-microarray technology to compare the
transcriptional response induced by CPT-dependent DNA
damage in two high-grade glioblastoma cell lines. Follow-
ing TopoI inhibition, apoptosis and senescence were the
different fates of DBTRG-05 and U87-MG cells, respec-
tively. Some lines of evidence suggested that, in the pres-
Table 1: List of Genes up-regulated following CPT treatment in both U87-MG and DBTRG-05 cells.
GeneName Description
DNA-Damage and/or stress-responsive genes
ATF3 Activating transcription factor 3
CDKN1A Cyclin-dependent kinase inhibitor 1A
DDIT3 DNA damage inducible transcript 3
DUSP5 Dual specificity phosphatase 5
EGR1 Early growth response 1
EGR3 Early growth response 3
FDXR Ferredoxin reductase
GADD45A DNA damage inducible transcript 1
p53CSV p53-inducible cell-survival factor
PIG3 tumor protein p53 inducible protein 3
SAT Spermidine/spermine N1-acetyltransferase
TIEG TGFB inducible early growth response
TRIB3 tribbles homolog 3 (Drosophila)
miscellaneous
GA Breast cell glutaminase
I_1201768 Protein of unknown function
I_928877 Protein of unknown function
I_929113 Protein with very strong similarity to ribonucleotide reductase induced by p53 (human p53R2)
IL8 Interleukin 8
KLF5 Kruppel-like factor 5 (intestinal)
PPIF Peptidylprolyl isomerase F
SEI1 Cyclin-dependent kinase 4-binding protein
EDIL3 EGF-like repeats and discoidin I-like domains 3Page 6 of 16
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develop a senescence-like phenotype whereas undergo
apoptosis, if p53 is mutated [5]. Taking into account that
the two glioblastoma cell lines we used are both wild type
for p53 [26], we suggested that the mutational status of
p53 is not sufficient by itself to predict the CPT effects in
our cell model. The difference in p21 protein stability
between U87-MG and DBTRG-05 cells, already described
by Li and coworkers [26], probably plays a more impor-
tant role than the mutational status of p53 in the determi-
nation of the cell fate, senescence versus apoptosis. This
results, moreover, agrees with the data reported for p53
wild-type HCT166 colon carcinoma cells, in which the
ability of low doses of CPT to induce senescence and
actively inhibit apoptosis was correlated to the sustained
expression of p21 [4].
The overall transcriptional response, activated through a
72-hours time-course treatment with CPT, reflected, in
part, the divergent biological effects triggered by TopoI
inhibition. In fact, the number of genes, whose expression
was affected, was much higher in the cells undergoing
senescence rather than apoptosis. In addition, the dispro-
portion between down- and up-regulated genes suggested
that the development of senescence was accompanied by
a general inhibition of transcription, which seemed not to
affect, in a similar manner, the apoptotic DBTRG-05 cell
population. Interestingly "transcription from Pol II pro-
moter" was, indeed, one of the biological process identi-
fied by EASE analysis as significantly enriched in the list of
U87-MG down-regulated genes, where we found the
repression of many transcription factors mRNAs such as
AHR; CHD1; CNOT2; DEK; ELL2; EPAS1; ETV1; FOXC2;
FOXM1; GLI3; GTF2F2; HIPK2; HIRA; ID1; MNAT1;
MYC; NCOA6; NCOR1; NR2F2; PBX3; RB1; RBBP8;
SMARCA5; TCF4; TFDP1 and TRIP13.
In spite of the difference in the transcriptional profiles of
the two cell lines, the general picture of the biological
processes, returned by High-Troughput GoMINER and
expressed in terms of GO categories, that resulted as
mostly affected along the exposure time, highlighted the
similarities between the two data-sets. This could arise
from a general response to genotoxic stress induced by
CPT, independently from the fate followed by the dam-
aged cells (senescence or apoptosis). In fact, 60% of the
genes, that were modulated in apoptotic DBTRG-05 cells,
were regulated in senescent U87-MG cells, as well, and,
within this list, many genes were described to be induced
by DNA damage, as transcriptional targets of wild-type
p53, including: p21/waf1, GADD45A, ATF3, PIG3,
P53CSV, FDXR, DDIT3, KFL5 and BIRC5 [27]. In particu-
lar, a recent report has shown that BIRC5 (survivin),
which inhibits apoptosis and controls cell division [28],
was up-regulated in many brain cancers [29] but repressed
both in vitro and in vivo, following TopoI inhibition in
myeloid leukemia cells [15]. Noteworthy, regardless of
the outcome due to CPT treatment, BIRC5 was down-reg-
Table 2: Genes down-regulated following CPT treatment in both 
U87-MG and DBTRG-05
GeneName Description
DNA metabolism and replication
ADK Adenosine kinase
CDC45L Cell division cycle 45 like
DTYMK Deoxythymidylate kinase (dTMP kinase)
FEN1 Flap structure specific endonuclease 1
H2AFZ H2A histone family Z
KIAA0101 The PCNA-associated factor KIAA0101/p15(PAF)
MCM2 Mini chromosome maintenance deficient 2
MCM3 Minichromosome maintenance deficient 3
MCM7 Minichromosome maintenance deficient 7
RRM1 Ribonucleotide reductase M1 subunit,
RRM2 Ribonucleotide reductase subunit M2,
TYMS Thymidylate synthetase
UHRF1 Nuclear protein 95
Cell cycle and mitosis
ANKT nucleolar and spindle associated protein 1
BIRC5 Survivin
CCNA2 Cyclin A2
CDC2 Cell division cycle 2
CDCA5 cell division cycle associated 5
KNSL6 Mitotic centromere-associated kinesin (kinesin-like 6)
PRC1 Protein regulator of cytokinesis 1
STMN1 Stathmin 1 (oncoprotein 18)
TOPK PDZ-binding kinase
UBE2C Ubiquitin-conjugating enzyme E2C
ZWINT ZW10 interactor
Miscellaneous
DKFZp762E1312 Protein of unknown function
I_932099 Protein with high similarity to human HNRPA1,
ID1 Inhibitor of DNA binding 1
KPNA2 Karyopherin alpha 2 (importin alpha 1),
LOXL2 Lysyl oxidase-like 2
p100 EBNA-2 co-activator (100 kD)
SPOCK Testican
TSSC3 Tumor suppressing subtransferable candidate 3
UBE2T ubiquitin-conjugating enzyme E2T
Venn-diagram representation of gene transcripts up- (A) and down-re ulated (B) by CPT in either/both U87-MG and DBTRG-05 c ll linesFigure 4
Venn-diagram representation of gene transcripts up- 
(A) and down-regulated (B) by CPT in either/both 
U87-MG and DBTRG-05 cell lines.Page 7 of 16
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the relevance of this transcriptional target in the action of
this drug agent.
Most of the common repressed genes were involved in
DNA replication, mitosis and spindle organization. The
delayed expression of mitosis related genes was already
described in HCT116 non-apoptotic colon cancer cells,
treated with CPT [13], and this modulation was reported
as a common hallmark of the transcriptional effect
induced by the activation of the DNA damage G2-check-
point [30]. However, as highlighted by High-Throughput
GoMINER and EASE functional analysis, the mitotic
down-regulation induced by CPT was much more evident
in senescent U87-MG cells where, in particular, the inhi-
bition of several cyclins D1, E1, A2, B1 and B2, was
accompanied by the ipo-expression of genes belonging to
the mitotic spindle checkpoint pathway, such as MAD2,
BUB1 and BUB3. The spindle checkpoint function moni-
tors the completion of the spindle-kinetochore attach-
ment and is a crucial factor to ensure the accurate sister
chromatid segregation during cell division. In agreement
with spindle checkpoint dysfunction, we, indeed,
observed a slight increase of aneuploidy in U87-MG cells
at the latest time point. Our observation is consistent with
previous reports demonstrating that the down-regulation
of spindle checkpoint proteins preceded the induction of
senescence in human hepatoma cells exposed to a low
dose of doxorubicin [6] and that normal human diploid
fibroblasts underwent premature senescence in culture
when BUB 1 was silenced by RNAi [31]. Taken together
with other data, demonstrating that spindle checkpoint
compromised HCT116-MAD2+/-cells, efficiently escaped
from TopoI poison-induced apoptosis [32] and that
MAD2-silenced gastric cancer SGC7901 cells increased the
resistance to DNA damaging agents by up-regulating Bcl-
2 [33], it is reasonable to speculate that the induction of
senescence and the inhibition of apoptosis might be
linked to the ipo-expression of spindle checkpoint pro-
teins and that these proteins might also modulate the sen-
sibility to DNA damaging agents, such as TopoI
inhibitors.
In U87-MG but not in apoptotic DBTRG-05 cells, CPT
treatment also led to the down-regulation of TFDP1
(DRTF1 polypeptyde 1, DP1), a transcription factor that
Time-dependent expression profile of AREG, GEM, MYC and MIG6F gure 5
Time-dependent expression profile of AREG, GEM, MYC and MIG6. Log2 (expression ratio) was plotted versus time.Page 8 of 16
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plex with the E2Fs proteins family [34]. The depletion of
DP1 protein was recently reported to efficiently block E2F
transcriptional activity and trigger a senescence-like cell
cycle arrest [35]. Many of the genes involved in DNA rep-
lication and mitosis that were down-regulated in U87-MG
cells are indeed known as E2F target genes (TK1, RRM1,
RRM2, MCM3, MCM7, TOP2A, FEN1, RAD51, CDC2,
CyclinA2, CyclinB1, CyclinB2, BUB1, HMG2, Stathmin,
AnnexinVIII, Ki-67, RB etc) [36], suggesting a relevant role
of this pathway in the development of a senescent pheno-
type in U87-MG cells.
Among the genes that showed a different CPT-time-
dependent profile in the two cell lines, MYC was, by far,
the most important one, being involved in the regulation
of fundamental biological processes, such as apoptosis
and cell growth. In agreement with our evidence of MYC
induction in DBTRG-05 apoptotic cells, the over-expres-
sion of MYC was already described to sensitize colon can-
cer cells to CPT-induced apoptosis [38] and to be
necessary, in rat fibroblasts, for DNA damage-initiated
apoptosis in the G2 phase of the cell cycle [39]. On the
other hand, the down-regulation of MYC in U87-MG
cells, fits the result of a recently published paper where the
suppression of MYC oncogene triggers cellular senes-
cence, in diverse tumor types including hepatocellular car-
cinoma, osteosarcoma and lymphoma [40].
In a previous paper [19], we have already reported the
transcriptional profile of a CPT-resistant sub-line
U87CPT-R, selected through repeated cycles of high dose
Semi-quantitative RT-PCR post-validation of microarray resultsFigure 6
Semi-quantitative RT-PCR post-validation of microarray results. A. Gene expression changes for seven genes 
(CDKN1A, GADD45, TXNIP, MYC, GEM, AREG, EREG) were measured at selected time points after CPT treatment by 
semi-quantitative RT-PCR and normalized to β-actin expression of time- and dose- matched controls. The RT-PCR reactions 
were analyzed with the DNA1000 kit of the Agilent 2100 Bioanalyzer to give a gel-like image. B. At each selected time point 
after CPT treatment, expression fold change values obtained with semi-quantitative RT-PCR and microarrays were compared.Page 9 of 16
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cells over-produced IL-1beta, as well as other pro-inflam-
matory cytokines. We also found IL1-beta induction in
senescent U87-MG cells obtained after three months of
continuous culturing with gradually increasing of CPT
concentrations (from 1 nM to 100 nM), thus demonstrat-
ing that the transcriptional induction of IL-1beta was a
common hallmark of prolonged CPT treatment. In the
present time-course study, the "late" (after 48h-treatment)
induction of IL-1beta by CPT, together with other proteins
known to be involved in regulation of immune response
and/or response to stress, was confirmed in U87-MG cells
but not in the apoptotic DBTRG-05 cell line. This data
suggest that the positive modulation of this cytokine
might have a strict correlation with the development and
maintenance of a senescent phenotype.
This hypothesis is strengthened not only by the general
consideration that the inflammatory response accompa-
nies the aging process [41] but also by the finding that the
transcriptional analysis of senescent fibroblasts showed
the up-regulation of IL-1beta mRNA [42].
To demonstrate a direct link between IL-1beta and the
phenotype observed in CPT- treated U87-MG cells, we
used a gene silencing approach. The results showed that,
in spite of an efficient knocking down of the IL-1beta
expression, silenced U87-MG still developed senescence,
after a 72 h CPT-treatment, thus suggesting that IL-1beta
had only a marginal role in senescence development and
maintenance.
This observation raises the question about the real signif-
icance that IL-1beta over-production and the following
burst in inflammatory response might have, mostly in
relation to prolonged treatment with TopoI inhibitors. In
fact the persistent production of pro-inflammatory
cytokines by senescent cells, that remain metabolically
active at tumor site, might actually reduce the efficacy of
CPT. It is, indeed, well accepted that inflammation had a
great impact on the stimulation of tumor-growth, inva-
siveness and angiogenesis [43] and that the over-expres-
sion of IL-1beta by the tumor microenvironment favors
the process of carcinogenesis and strengthens invasiveness
of already existing malignant cells [44,45], thus clearly
influencing the outcome of anticancer therapy.
Conclusion
Our data provided new insight into the transcriptional
response programs induced by CPT in a cell-culture based
glioblastoma model and showed that, besides a great dif-
ference in the effector program triggered by CPT (senes-
cence vs. apoptosis), we can detect a common
transcriptional signature representative of the early cellu-
lar response to CPT-induced genotoxic stress. Neverthe-
less, we observed that several gene expression changes
account for the divergent biological effects induced by
CPT, in our model. The down-regulation of MAD2, BUB1
and BUB3 mitotic spindle checkpoint proteins together
with the repression of the transcription factors DP1 and
MYC were suggested as key elements in the regulation of
drug-mediated senescence in U87-MG cells. In addition,
by analyzing the role of IL-beta 1 up-regulation in senes-
cent cells, we opened new insights into the importance
Table 3: List of genes belonging to some of the most significantly 
down-regulated GO categories as resulted by GoMiner 
Hightroughput analysis
Cell Cycle DNA metabolism M-Phase
U87 DBTRG U87 DBTRG U87 DBTRG
CDC45L MCM7 CDC6 UBE2C POT1 MCM7
MCM3 CDC45L PRC1 CDC2 CDC45L CDC45L
PRC1 MCM3 BUB1 STMN1 MCM3 RRM2
TFDP1 PRC1 MAD2L1 PRC1 FEN1 MCM3
CKS2 TOPK TOPK KPNA2 PRIM2A KPNA2
MAD2L1 UHRF1 CCNA2 TOPK EZH2 FEN1
EXT1 CCNA2 KNSL5 CCNA2 USP1 UHRF1
CCNB2 CDC2 UBE2C RFC3 DTYMK
CDKN2D UBE2C CCNB2 RAD54B RRM1
RAD54B ZWINT CDC2 TOP2A TYMS
BIRC5 STMN1 STMN1 MCM6 MCM2
MCM6 KPNA2 KPNA2 TYMS
TTK BIRC5 PKMYT1 NFIB
CDKN3 DTYMK RAD54B MID1
TOPBP1 MCM2 CCNB1 TOPBP1
CDC6 TTK CDC6
MCM7 SMC2L1 PRKDC
MNAT1 MCM7
DLG1 MNAT1
BUB1 RFC5
UHRF1 UHRF1
NOTCH2 RRM1
TOPK HMG1
CCNA2 RRM2
KNSL5 NT5E
CDC2 KPNA2
UBE2C MSH2
BARD1 HMG2
ZWINT DTYMK
CKS1 MCM2
MKI67
STMN1
MSH2
KPNA2
PKMYT1
CCNB1
RB1
DTYMK
CCNE2
MCM2
SMC2L1Page 10 of 16
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chemotherapy outcome.
In conclusion, our transcriptional analysis contributes to
the search for potential biomarkers of CPT response in
glioblastoma cells and add information to define the out-
come of anticancer therapy in this model system.
Methods
Cell lines
U87-MG and DBTRG-05 glioblastoma cell lines were pur-
chased from the American Type Culture Collection (Man-
assas, VA), and grown in a humidified atmosphere of 5%
CO2 at 37°C in MEM culture medium (Invitrogen,
Carlsbad, CA) supplemented with 10% Fetal Bovine
Serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 17.8
mM sodium bicarbonate, 0.1 mM non-essential aminoac-
ids and in RPMI culture medium supplemented with 10%
Fetal Bovine Serum and 2 mM L-glutamine (Invitrogen,
Carlsbad, CA), respectively. S-(+)-camptothecin was pur-
chased from Sigma (St. Louis, MO) and dissolved to a
concentration of 3 mM in DMSO.
Acute cytotoxicity assay
The concentration of CPT that induced 50% inhibition of
cell growth (GI50) was determined by staining cells with
crystal violet according to the protocol described previ-
ously (19). Cells were seeded at 2 × 105 cells per plate, in
60 mm Ø plates, allowed to attach for 24 h and subse-
quently exposed to CPT. One plate in triplicate was fixed
before CPT treatment in order to measure the cell popula-
tion at the time of drug addition (Tz). The GI50 was cal-
culated according to the protocol used in the "In vitro
Anticancer Discovery screen program" of the National
Cancer Institute http://dtp.nci.nih.gov/branches/btb/
ivclsp.html.
Annexin-V apoptosis assay
To evaluate the percentage of apoptotic and necrotic cells,
after a 24 h treatment with CPT, 5 × 104 cells were
detached from the plates and incubated with 50 μl of labe-
ling solution containing Annexin-V-FLUOS reagent
(Roche Diagnostics GmbH, Mannheim, Germany)
diluted in Hepes buffer and 1 μg/ml propidium iodide
(Sigma), for 10–15 minutes at room temperature. The
cells were then counted under fluorescence.
BrdU labeling and Flow cytometric analysis
Adherent cells were pulsed with 30 μM BrdU (Sigma) for
30 min. at 37°C. After two washing steps with 1% BSA/
PBS cells were fixed in 5 ml 70% ethanol for 30 min and
then centrifuged at 1500 × g for 10 min. Single stranded
DNA was produced by incubating fixed cells with 2N HCl/
Triton X100 for 30 min at room temperature. After two
Table 4: List of the biological processes as defined by the Gene Ontology that resulted enriched in the list of up-redulated and down-
regulated genes in U87-MG and DBTRG-05 by EASE analysis (EASE score, Bonferroni < 0.05)
U87 DOWN DBTRG DOWN
Cell cycle Mitotic cell cycle
Mitotic cell cycle Cell cycle
Cell proliferation Cell proliferation
Cell growth and maintenance DNA metabolism
Cellular process Deoxyribonucleic acid metabolism
DNA replication and chromosome cycle
DNA replication
S-phase of mitotic cell cycle
Mitosis
M-phase of mitotic cell cycle
DNA metabolism
DNA dependent DNA replication
Cell cycle checkpoints
M-phase
Nuclear division
G1-S transition of mitotic cell cycle
U87 UP DBTRG UP
Negative regulation of cell proliferation N.A.
Regulation of cellular process
Regulation of biological process
Regulation of cell proliferation
Response to external stimulus
Cell proliferation
Response to stressPage 11 of 16
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0.5%Tween 20/1% BSA/PBS and incubated with 20 μl of
Anti-BrdU FITC (Becton Dickinson, San Josè, CA) for 30
min at room temperature. Washed cells were then re-sus-
pended in 1 ml of PBS containing 50 μg/ml propidium
iodide. The analysis of DNA content and cell cycle were
performed using a FACSCalibur equipped with 488 nm
laser (Becton Dickinson, San Jose, CA, USA) and Cells
Quest software (10.000 cells analyzed for each sample).
SA-β-Gal staining
To detect senescence – associated – β-galactosidase (SA-β-
gal) activity, cells were washed twice in PBS and fixed in a
buffer containing 2% formaldehyde and 0.2% glutaralde-
hyde in PBS for 5 min. at room temperature (Sigma). SA-
β-gal staining was then performed using a citric acid/
phosphate buffer (pH 6.00) containing 1 mg/ml of X-Gal,
5 mM potassium ferricyanide, 5 mM potassium ferrocya-
nide, 2 mM MgCl2 and 150 mM NaCl (Sigma). A blue
color was visible in senescent cells within 2 h but reached
the maximum between 12 to 16 h. At that time, counts
were made on three random fields of about 100 cells.
RNA preparation and hybridization
Total RNA was isolated from exponentially growing cells
using TRIzol Reagent (Life Technologies, Carlsbad, CA)
and purified on RneasyR affinity column (Qiagen, Valen-
cia, CA). The quality of RNA was assessed with the Agilent
bioanalyzer 2100 using the RNA nano kit (Agilent Tech-
nologies, Palo Alto, CA). cDNA was synthesised from 20
μg of total RNA and labelled with Cy3-dCTP or Cy5-dCTP
(Perkin-Elmer, Boston, MA) following in details the man-
ufacturer protocol (Agilent fluorescent direct label kit,
G2555-98003, version 2.1. available online at http://
Effects of IL-1beta gene silencing on CPT-induced senescence in U87-MG cellsFigure 7
Effects of IL-1beta gene silencing on CPT-induced senescence in U87-MG cells. A. Real- time analysis of IL-1beta 
gene silencing. IL-1beta mRNA levels were significantly reduced (** p < 0.01, Student's t-test) with respect to mRNA level of 
the non silenced CPT-treated cells. IL1-B relative expression was obtained by performing the comparative method [48]. Firstly, 
data were normalized to GAPDH, then to a calibrator, consisting of mRNA obtained from CPT treated cells. The results were 
expressed as 2^-ΔΔCt, where ΔCt of each sample was defined as Ct(target gene = IL1-beta) - CtGAPDH, and ΔΔCt = ΔCt(sample = cDNA from 
CPT+iRNAs treated cells) - ΔCt calibrator(cDNA from CPT treated cells). ΔΔCt calibrator is always equal to 0 so that 2^-ΔΔCt is always 1. B. 
SA-β gal activity, in response to 1 μM CPT, was quantified in U87-MG cells in the presence or in the absence of IL-1beta gene 
silencing. DMSO, solvent control. Bars, standard error. * p < 0.05, Student's t-test. C. 250 cells from either CPT and solvent 
exposed cells or IL-1beta-silenced/CPT-treated U87-MG cells were sub-cultured in fresh medium in five replicates. Cells were 
maintained in culture for 10 days, with bi-weekly medium changes, then were fixed with methanol, stained with 10% aqueous 
Giemsa and scored for colony formation. Only colonies containing more than 50 cells were counted. Clonal efficiency was cal-
culated as the mean number of colonies per plate with respect to the solvent. Bars, standard error. * p < 0.05, Student's t-test. 
** p < 0.01, Student's t-test.Page 12 of 16
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oligo-microarray Kit. Labelled cDNA from the two reac-
tions was combined, purified with QIAquick spin column
(Qiagen), and then applied to the oligonucleotide slide
(Human1A oligo microarray, G4110A) according to the
Agilent 60-mer oligo microarray processing protocol
(G4140-90010 version 7.1. available online at http://
www.chem.agilent.com). Slides were scanned in both Cy-
3 and Cy-5 channels with Agilent dual laser microarray
scanner (G2565AA). Scanned images were analyzed by
the Agilent Feature Extraction software 7.5 to derive the
raw intensity data used in the next steps of analysis. The
raw data discussed in this publication have been depos-
ited in Arrayexpress, the EBI microarray data public repos-
itory (Arrayexpress http://www.ebi.ac.uk/arrayexpress/).
The U87-MG has been assigned the accession number: E-
MEXP-741. The DBTRG- has been assigned the accession
number: E-MEXP-751.
Experimental design and microarray data analysis
For each cell line we adopted an experimental design con-
sisting of six after-treatment time points (2 h, 6 h, 16 h, 24
h, 48 h, 72 h) compared to an untreated zero-time com-
mon reference. Total RNA samples, corresponding to each
time point, were derived from a pool of RNAs extracted
from three independent experiments. Each time point was
replicated by performing a dye-swap. The data-sets of the
two time-series experiment underwent preliminary data
filtering procedures. Data, corresponding to features
flagged as controls, were filtered out before proceeding to
the following analysis. Filtered raw (median green and red
signal) intensity (17874 features for the "U87_CPT" and
17905 features for the "DBTRG_CPT") were then log2-
tranformed and normalized intra-array for intensity- and
position-dependent bias using the Joint-LOWESS algo-
rithm.
To assess differentially expressed genes, the transformed
data were analyzed by using MAANOVA (Micro Array
ANalysis Of VAriance) data analysis package of R pro-
gramming environments [23]. The fixed-effect linear
ANOVA model, yijkg = μ + Ai + Dj + Tk + Gg + AGig + DGjg +
TGkg + εijkg, was chosen to fit transformed intensity data y,
where μ is the overall mean expression level and εijkg is the
residual measurement effect. This model allows you to
take into account the different sources of variance of an
experiment due to array (A), dye (D), gene (G), time
points (T) and to their combined effects (AG, DG and TG).
The term TG is that of primary interest in our analysis; it
captures variations in the expression levels of a gene
across the time points.
We then tested a null hypothesis of no differential expres-
sion (so that all TG values are equal to zero) using F statis-
tics computed on the James-Stein shrinkage estimates of
the error variance [46]. To avoid any assumption on error
distribution, the package offers the possibility of comput-
ing p-values for hypothesis tests via permutation methods
(in our analyzes 1000 permutations with sample shuffling
were carried out). Finally the false-discovery rate control-
ling method [47] was used to correct significance estimate
for multiple testing hypothesis. In the analysis of the
"U87_CPT" we selected, as differentially expressed, the
features with p < 0.01 in the F test, after false-discovery
rate adjustment, while in the analysis of the
"DBTRG_CPT", the chosen threshold p-value was 0.05.
Therefore, 3168 and 155 genes were deemed as signifi-
cantly modulated in the "U87_CPT" and the
"DBTRG_CPT" analysis, respectively.
High-throughput GoMiner and EASE analysis of 
microarray data
High-throughput GoMiner, calculates for each category
the enrichment factor Re = (nf/n)/(Nf/N), where nf is the
number of flagged genes within the category (i.e., genes
whose expression levels are considered to be changed
beyond a given threshold), n is the total number of genes
within that same category, Nf is the number of flagged
genes on the entire microarray, and N is the total number
of genes on the microarray. For each category a Fisher's
exact p-values (for the one-tailed test) was calculated to
measure its statistical significance. Furthermore to address
the question of multiple comparisons the program also
estimates the False discovery rate (FDR) by using a re-sam-
pling algorithm.
EASE first calculates the List Hits (number of genes in the
gene list that belong to the Gene Category), the List Total
(number of genes in the gene list), the Population Hits
(number of genes in the total group of genes assayed that
belong to the specific Gene Category) and the Population
Total (number of genes in the total group of genes assayed
that belong to any Gene category within the system). Then
the probability of seeing the number of "List Hits" in the
"List Total" given the frequency of "Population Hits" in
the "Population Total" is calculated as the Fisher exact
probability. EASE also calculate another metric known as
the "EASE score" which is the upper bound of the distri-
bution of Jackknife Fisher exact probabilities. The EASE
score is a conservative adjustment of the Fisher exact that
strongly penalizes the significance of categories supported
by few genes. Moreover in order to address the multiple
comparisons problem we used Bonferroni method to cor-
rect the EASE score.
Semi-quantitative RT-PCR
Some gene expression changes detected in the microarray
were validated by semi-quantitative Rt-PCR. 1 μg of total
RNA was retro-transcribed to cDNA using 200 Units of
SuperScript II RnaseH- Reverse Transcriptase (Life Tech-
nologies), with 25 μg/ml oligo(dT) primer and 500 μM
dNTP mix.Page 13 of 16
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using less than 10% of the RT reaction, with 5 Units of Taq
DNA polymerase (Life Technologies), 1.5 μM MgCl2, 200
μM dNTP mix and 20 μM forward/reverse primers for: IL-
1ß (5'gggcctcaaggaaaagaatc3'/5'ttctgcttgagaggtgctga3'),
EREG (5'cctggtgcacagtgcttaga3'/5'actccccagggttagcttgt3'),
GEM (5'gggagagagtgggagtttcc3'/5'aaagatgttggccagagtgg3'),
MYC (5'ctcctggcaaaaggtcagag3'/5'ggccttttcattgttttcca3'),
TXNIP (5'gccacacttaccttgccaat3'/5'ggaggagcttctggggtatc3'),
AREG (5'tggattggacctcaatgaca3'/5'ccatttttgcctcccttttt3'),
GADD45(5'ggaggaagtgctcagcaaag3'/
5'tcccggcaaaaacaaataag3'), CDKN1A
(5'gacaccactggagggtgact3'/5'tggattagggcttcctcttgg3')
(Sigma). Reactions were run on GeneAmp PCR System
9600 (Applied Biosystems Foster City, USA).
The amplified fragments were analyzed and quantified
using the DNA1000 kit of the Agilent 2100 Bioanalyzer.
siRNA and quantitative real-time PCR
We used two different HP GenomeWide siRNA duplexes
against IL-1beta (IL1B_4_HPsiRNA and
IL1B_6_HPsiRNA, Qiagen). U87-MG cells were trans-
fected with HiPerFect Trasfection Reagent (Qiagen)
according to the manufacturer's protocol, using a final
concentration of 10 nM siRNA. The transfection efficiency
was tested by a non-silencing control siRNA, labeled with
Alexa Fluor 488 (Qiagen). Gene silencing was checked by
real-time RT-PCR using the SYBR Green qPCR Supermix
(Invitrogen) and two different forward/reverse primers for
IL-1beta (a: 5'aaacctcttcgaggcacaag3'/
5'ctgtttagggccatcagctt3'; b: 5'gggcctcaaggaaaagaatc3'/
5'ttctgcttgagaggtgctga3'), depending on the siRNA target
sequence.
Total RNA was extracted using TriZol reagent and purified
on RNeasyR mini affinity column kit (Qiagen), and cDNA
was synthesized with the SuperScript™ III First-Strand Syn-
thesis SuperMix (Invitrogen). The level of test cDNA rela-
tive to that of GAPDH was calculated by the 
method. [46]
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